Kapil Dhingra sold $33k of REPL
director at Replimune Group, Inc.. 3,169 shares at an average of $10.40, traded Dec 9, 2025, filed Dec 11, 2025.
Score components
- +15RoleDirector
- +6Trade size$33k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -18.6%, 3m -23.2%, 6m -12.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-120332, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2025 | MOption exercise Common Stock | +3,169 | $1.75 | $5,546 | 3,169 | Dec 11, 2025 |
| Dec 9, 2025 | SOpen-market sale Common Stock | -3,169 | $10.40 | $33k | 0 | Dec 11, 2025 |
| Dec 9, 2025 | MOption exercise Stock Option (right to buy)derivative | -3,169 | $0.00 | $0 | 0 | Dec 11, 2025 |
Related signals
Other insiders at Replimune Group, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | Replimune Group, Inc. | Emily Luisa Hill Chief Financial Officer | $132k 9,256 shares | -4% | |
| 48Moderate | Replimune Group, Inc. | Emily Luisa Hill Chief Financial Officer | $148k 11,448 shares | -5% | |
| 58Moderate | Replimune Group, Inc. | Sushil Patel Chief Executive Officer | $510k 39,341 shares | -5% | |
| 40Moderate | Replimune Group, Inc. | Andrew Schwendenman Chief Accounting Officer | $99k 7,632 shares | -7% | |
| 41Moderate | Replimune Group, Inc. | Konstantinos Xynos Chief Medical Officer | $148k 11,447 shares | -5% | |
| 20Weak | Replimune Group, Inc. | Christopher Sarchi Chief Commercial Officer | $111k 12,000 shares | -6% | |
| 39Weak | Replimune Group, Inc. | Philip Astley-Sparke Executive Chairman | $90k 17,657 shares | -1% | |
| 43Moderate | Replimune Group, Inc. | Emily Luisa Hill Chief Financial Officer | $40k 7,812 shares | -3% | |
| 52Moderate | Replimune Group, Inc. | Sushil Patel Chief Executive Officer | $190k 37,324 shares | -5% | |
| 36Weak | Replimune Group, Inc. | Christopher Sarchi Chief Commercial Officer | $44k 8,626 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.